Compare BRLT & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRLT | GRDX |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5M | 28.6M |
| IPO Year | 2021 | 2016 |
| Metric | BRLT | GRDX |
|---|---|---|
| Price | $1.52 | $4.82 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $1.62 | N/A |
| AVG Volume (30 Days) | 58.8K | ★ 109.3K |
| Earning Date | 11-05-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.95 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $437,483,000.00 | N/A |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $5.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $1.00 | $1.87 |
| 52 Week High | $2.90 | $6.93 |
| Indicator | BRLT | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 52.79 |
| Support Level | $1.26 | $2.35 |
| Resistance Level | $1.63 | $5.04 |
| Average True Range (ATR) | 0.08 | 0.54 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 63.64 | 38.17 |
Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.